SCHEMBL325811

SCHEMBL325811

COCC(Nc1cc(C#CC(C)(C)C)sc1C(=O)O)C(=O)N1CCOCC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2E1 P05181 1/20 0.46
NR1I2 O75469 2/20 0.34
TACR1 P25103 2/20 0.34
CTSS P25774 1/20 0.32
POLB P06746 2/20 0.31
MMP8 P22894 1/20 0.31
ALOX15 P16050 1/20 0.31
HSD17B10 Q99714 1/20 0.31
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
ADRB2 P07550 1/20 0.31
ADRB1 P08588 1/20 0.31
ADRB3 P13945 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
KMT2A Q03164 1/20 0.31
FKBP1A P62942 1/20 0.31
RAB9A P51151 1/20 0.31
CNR1 P21554 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15130726 1.00 CYP2E1 (0.46) CYP2E1NR1I2TACR1CTSSPOLB
SCHEMBL326053 0.93 CYP2E1 (0.41) CYP2E1TACR1POLBALOX15HSD17B10
SCHEMBL326054 0.93 CYP2E1 (0.41) CYP2E1TACR1POLBALOX15HSD17B10
SCHEMBL15130796 0.86 CYP2E1 (0.40) CYP2E1TACR1POLBALOX15HSD17B10
SCHEMBL15124048 0.84 CYP2E1 (0.41) CYP2E1TACR1POLBALOX15HSD17B10
SCHEMBL325018 0.84 CYP2E1 (0.41) CYP2E1TACR1POLBALOX15HSD17B10
SCHEMBL325017 0.84 CYP2E1 (0.41) CYP2E1TACR1POLBALOX15HSD17B10
SCHEMBL15130678 0.84 NR1I2 (0.33) CYP2E1NR1I2ALDH1A1KMT2A
SCHEMBL15130663 0.83 CYP2E1 (0.40) CYP2E1TACR1POLBALOX15HSD17B10
SCHEMBL325327 0.79 CYP2E1 (0.41) CYP2E1POLBALOX15HSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-25 US disclosed
EP-2585447-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS Vertex Pharmaceuticals Incorporated (US) 2013-05-01 EP disclosed
WO-2012006055-A2 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190289-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS SLC10A1, ACE, CEL CYP2E1 1027/4885NR1I2 1500/4885TACR1 3047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.